PP
TVRD

Paloma Partners’s Tvardi Therapeutics TVRD Stock Holding History

Paloma Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,528
Closed -$14.2K – 1764
2024
Q2 		$14.2K Buy
+1,528
New +$36.5K ﹤0.01% 1198
2020
Q1 		– Sell
-304
Closed -$176K – 2209
2019
Q4 		$176K Buy
+304
New +$213K ﹤0.01% 1994
2018
Q1 		– Sell
-378
Closed -$167K – 2318
2017
Q4 		$167K Buy
+378
New +$172K ﹤0.01% 1755

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's TVRD Position: Q3 2024 in Review

Paloma Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 1,528 shares — an estimated $14.2K sold.

Paloma Partners first reported a position in TVRD in Q4 2017 and held it in 3 quarters. The position peaked at $176K in Q4 2019. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Paloma Partners reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 1,528 Tvardi Therapeutics shares in Q3 2024, an estimated $14.2K.
  • Paloma Partners first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 3 quarters.
  • Paloma Partners's Tvardi Therapeutics position peaked at $176K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.